Physician profile
Morgan Stoneman
NPI 1518542844
$4,097.45
in general payments reported to CMS, 2019-2025
34 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,803 · 2023: $1,713 · 2024: $242 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,218 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.53 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,031.09 | 2022-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $491.37 | 2022-2023 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $405.13 | 2022-2023 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Mylan Specialty L.P. | $307.10 | 2022-2023 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $187.62 | 2022-2023 | Opsumit, Uptravi |
| Novo Nordisk INC | $154.17 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $150.08 | 2022-2024 | Otezla, Repatha, Tezspire |
| Philips North America LLC | $149.75 | 2022-2023 | |
| Harmony Biosciences LLC | $130.25 | 2022-2023 | Wakix |
| Regeneron Healthcare Solutions, INC. | $104.13 | 2022-2023 | Dupixent |
| Abbvie INC. | $102.79 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $93.45 | 2022-2023 | Acthar |
| Lilly USA, LLC | $70.58 | 2023-2025 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $63.49 | 2022-2023 | Airduo Digihaler |
| Electromed, INC. | $53.19 | 2022-2023 | Smartvest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $49.16 | 2022-2023 | Glassia |
| Covis Pharma Gmbh | $47.61 | 2022 | |
| Axsome Therapeutics, INC. | $47.43 | 2023 | Sunosi |
| Otsuka America Pharmaceutical, INC. | $46.42 | 2024-2025 | Rexulti |
| Grifols USA, LLC | $45.55 | 2022-2023 | Prolastin-C Liquid |
| Organon LLC | $44.41 | 2024-2025 | Nexplanon, Nuvaring |
| Resmed Corp | $39.31 | 2022 | |
| Neurelis, INC. | $39.25 | 2023-2025 | Valtoco |
| Exact Sciences Corporation | $33.81 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Genzyme Corporation | $28.29 | 2022 | |
| Penumbra, INC. | $26.88 | 2022-2023 | Indigo System |
| Ars Pharmaceuticals Operations, INC. | $24.06 | 2025 | Neffy |
| Janssen Pharmaceuticals, INC | $23.04 | 2025 | Spravato |
| United Therapeutics Corporation | $22.99 | 2023 | Tyvaso |
| Verona Pharma, INC. | $20.94 | 2025 | Ohtuvayre |
| Esperion Therapeutics, INC. | $19.16 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $16.73 | 2024 | |
| Astellas Pharma US INC | $15.41 | 2024 | Veozah |
| Insmed, INC. | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Stoneman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.